DTC Act of 2025

Bill Summary: DTC Act of 2025 (HR 3789)

Overview

The Drug-price Transparency for Consumers Act of 2025 (DTC Act of 2025) is a legislative proposal designed to increase price transparency in pharmaceutical marketing. The bill requires pharmaceutical companies to disclose the list price of prescription drugs and biological products directly within their consumer-facing advertisements.

The primary intent of the bill is to empower consumers to make more informed financial and medical decisions and to reduce the influence of high-cost brand-name drugs that are aggressively marketed but may have more affordable alternatives.

Key Provisions

1. Mandatory Price Disclosure

The bill mandates that any direct-to-consumer (DTC) advertisement for a prescription drug or biological product must "clearly and conspicuously" disclose the Wholesale Acquisition Cost (WAC).
* Scope: This applies to drugs and biologicals for which payment is available under Medicare (Title XVIII) or Medicaid (Title XIX).
* Measurement: The price must be listed for a 30-day supply or a typical course of treatment as defined by the FDA-approved label.
* Caveat: Advertisers are permitted to include a disclaimer stating that the actual cost to the consumer may vary based on their specific health insurance coverage.

2. Exemptions

The price disclosure requirement does not apply to any medication with a Wholesale Acquisition Cost of less than $35 for a 30-day supply (or a typical course of treatment).

3. Enforcement and Penalties

To ensure compliance, the bill establishes significant financial deterrents:
* Civil Penalties: Manufacturers or their agents who violate these disclosure requirements may be subject to a civil money penalty of up to $100,000 per violation.
* Oversight: The Secretary of Health and Human Services (HHS) is authorized to use public reporting and other information to monitor and enforce compliance.

Who Is Affected?

• Pharmaceutical Manufacturers: Companies producing brand-name drugs and biologicals must overhaul their advertising materials to include pricing and update them whenever the WAC changes.
• Consumers/Patients: Individuals will have immediate access to the "list price" of a drug before consulting a physician, potentially reducing "sticker shock" at the pharmacy.
• Healthcare Providers: Doctors may see a shift in patient requests as consumers become more aware of the cost differences between brand-name and generic options.
• Government Payers: Medicare and Medicaid may see a reduction in wasteful spending if consumers and doctors shift toward more cost-effective therapies.

Timeline and Procedural Aspects

• Rulemaking: The Secretary of HHS must promulgate final regulations within one year of the Act's enactment. These regulations will define the specific visual and audio requirements for the price disclosures across different media.
• Implementation Deadline: The price disclosure requirements must be fully implemented no later than July 1, 2026.
• Current Status: As of June 5, 2025, the bill has been introduced in the House and referred to the Committees on Energy and Commerce and Ways and Means.